header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-8500
Fish name: la116Tg
Genotype: la116Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by la116Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Wang et al., 2017
cancer xenotransplantation Gao et al., 2017
cancer xenotransplantation Schaefer et al., 2015
squamous cell carcinoma cancer xenotransplantation von Mässenhausen et al., 2016
GENE EXPRESSION
Gene expression in la116Tg
RNA expression
Expressed Gene Structure Conditions Figures
adgrg6 standard conditions Fig. 4 from Cui et al., 2014
adora2b standard conditions Fig. 2 from Jing et al., 2015
alcama standard conditions Fig. 2Fig. S7 from Lagendijk et al., 2011
Fig. 1 with image from Smith et al., 2011
chemical treatment: pharmaceutical Fig. 7 from Lagendijk et al., 2011
bmp2b standard conditions Fig. S3 with image from Mouillesseaux et al., 2011
bmp4 standard conditions Fig. S3 with image from Mouillesseaux et al., 2011
dld standard conditions Fig. 1 with image from Fujita et al., 2011
egr2b standard conditions Fig. S1 with image from Mouillesseaux et al., 2011
flt4 standard conditions Fig. 2 with image from Mouillesseaux et al., 2011
ftr82 standard conditions Fig. 2 with image from Chang et al., 2017
hey2 standard conditions Fig. 2 with image from Mouillesseaux et al., 2011
itgav control Fig. 2 with image from Liu et al., 2012
itgb8 control Fig. 2 with image from Liu et al., 2012
kdrl standard conditions Fig. 4 from Cui et al., 2014
mir24-1 control Fig. 1 with image from Kasper et al., 2017
mir24-2 control Fig. 1 with image from Kasper et al., 2017
mir24-3 control Fig. 1 with image from Kasper et al., 2017
mir24-4 control Fig. 1 with image from Kasper et al., 2017
mir139 control Fig. 1 with image from Kasper et al., 2017
mir223 control Fig. 1 with image from Kasper et al., 2017
myb standard conditions Fig. S1 with image from Mouillesseaux et al., 2011
myod1 standard conditions Fig. 4 from Cui et al., 2014
nlgn1 standard conditions Fig. S1 from Rissone et al., 2012
nrxn1a standard conditions Fig. S1 from Rissone et al., 2012
tbx20 standard conditions Fig. 6 with image from Mouillesseaux et al., 2011
thbs1b standard conditions Fig. 6 with imageFig. S4 with image from Mouillesseaux et al., 2011
tjp1a standard conditions Fig. S4 with image from Liu et al., 2012
tp53 standard conditions Fig. S4 with image from Mouillesseaux et al., 2011
utp15 standard conditions Fig. 5 with image from Mouillesseaux et al., 2011
vegfaa standard conditions Fig. S3 with image from Mouillesseaux et al., 2011
xgb standard conditions Fig. 2 from Corti et al., 2016
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions Fig. 10 with image from Gao et al., 2017
Fig. 1 with image from Nicoli et al., 2012
Fig. 1Fig. 3Fig. 4 from Nicoli et al., 2010
chemical treatment: pharmaceutical Fig. 10 with image from Gao et al., 2017
Fig. 1 from Nicoli et al., 2010
cancer xenotransplantation Fig. 5 from Wang et al., 2017
Fig. 5 with image from Zhang et al., 2017
GFP standard conditions 70 figures with image from 36 publications
chemical treatment by environment: LY 364947 15 figures with image from 12 publications
chemical treatment by injection: docetaxel anhydrous, cancer xenotransplantation Fig. 6 with image from Kasper et al., 2017
Fig. 6 from Gao et al., 2015
Fig. 5 with image from Schaefer et al., 2015
Fig. 6Fig. 7 from Wu et al., 2013
PHENOTYPE
Phenotype in la116Tg
Phenotype Conditions Figures
angiogenesis decreased process quality, abnormal chemical treatment by environment: doxorubicin, chemical treatment by environment: methoxypoly(ethylene glycol), chemical treatment by environment: poly(caprolactone) polymer, chemical treatment by environment: Honokiol Fig. 10 with image from Gao et al., 2017
aortic arch 5 absent, abnormal chemical treatment: pharmaceutical Fig. 1 from Nicoli et al., 2010
aortic arch 5 absent, abnormal chemical treatment: pharmaceutical Fig. 1 from Nicoli et al., 2010
aortic arch 5 absent, abnormal chemical treatment: semaxanib Fig. 1 from Nicoli et al., 2010
atrioventricular valve malformed, abnormal chemical treatment by environment: ethanol Fig. 3 with imageFig. 4 with image from Sarmah et al., 2016
atrioventricular valve morphology, abnormal chemical treatment by environment: ethanol Fig. 3 with imageFig. 4 with image from Sarmah et al., 2016
atrioventricular valve shape, abnormal chemical treatment by environment: ethanol Fig. 4 with image from Sarmah et al., 2016
atrium position, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
basal communicating artery increased size, abnormal chemical treatment: LY-411575 Fig. 5 from Rochon et al., 2015
cardiac ventricle decreased size, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cardiac ventricle orientation atrium, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cardiac ventricle orientation atrioventricular valve, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cardiac ventricle position, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
cranial blood vessel artery morphogenesis process quality, abnormal chemical treatment: LY-411575 Fig. 5 from Rochon et al., 2015
endocardial cell differentiation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 7 from Lagendijk et al., 2011
endothelial tip cell cell population proliferation decreased rate, abnormal chemical treatment: aphidicolin, chemical treatment: hydroxyurea Fig. 7 with image from Nicoli et al., 2012
endothelial tip cell cell population proliferation decreased rate, normal chemical treatment: LY294002 Fig. 7 with image from Nicoli et al., 2012
heart morphology, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2017
hyaluronan biosynthetic process increased occurrence, abnormal chemical treatment: pharmaceutical Fig. 7 from Lagendijk et al., 2011
intersegmental vessel decreased amount, abnormal chemical treatment by environment: doxorubicin, chemical treatment by environment: methoxypoly(ethylene glycol), chemical treatment by environment: poly(caprolactone) polymer, chemical treatment by environment: Honokiol Fig. 10 with image from Gao et al., 2017
intersegmental vessel decreased size, abnormal chemical treatment by injection: quercetin, chemical treatment by injection: poly(caprolactone) polymer, chemical treatment by injection: methoxypoly(ethylene glycol) Fig. 5 from Wu et al., 2013
intersegmental vessel incomplete structure, abnormal chemical treatment: borrelidin Fig. 5 with image from Mirando et al., 2015
intersegmental vessel truncated, abnormal chemical treatment: borrelidin Fig. 5 with image from Mirando et al., 2015
lateral dorsal aorta morphology, normal standard conditions Fig. 3 with image from Siekmann et al., 2009
primordial hindbrain channel morphology, normal standard conditions Fig. 3 with image from Siekmann et al., 2009
superior ocular sulcus blood vessel increased amount, abnormal chemical treatment by environment: Cyclopamine Fig. S7 with image from Hocking et al., 2018
superior ocular sulcus blood vessel mislocalised, abnormal chemical treatment by environment: Cyclopamine Fig. S7 with image from Hocking et al., 2018
superior ocular sulcus blood vessel morphology, abnormal chemical treatment by environment: Cyclopamine Fig. S7 with image from Hocking et al., 2018
trunk vasculature morphology, normal chemical treatment by environment: prinomastat hydrochloride Fig. 2 with image from Theodore et al., 2017
trunk vasculature morphology, normal chemical treatment by environment: N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide Fig. 2 with image from Theodore et al., 2017
trunk vasculature morphology, normal chemical treatment by environment: MMP9 inhibitor I Fig. 2 with image from Theodore et al., 2017
trunk vasculature morphology, normal standard conditions Fig. 3 with image from Siekmann et al., 2009
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell GFP expression spatial pattern, abnormal chemical treatment by environment: prinomastat hydrochloride Fig. 2 with image from Theodore et al., 2017

CITATIONS  (87)